<p>美銀證券發佈報告稱，百濟神州（06160.HK）+1.100 (+0.610%) 空頭頭寸為 5562 萬美元；比例為 15.363%。2 月份在中國的樣本藥品總銷售額為人民幣 6.024 億元，同比增長 17.7%。自研和引進產品的銷售額分別達到人民幣 3.322 億元和人民幣 2.698 億元，分別同比增長 20.3% 和 14.5%。其中，2 月份的替雷利珠單抗和扎努布單抗的銷售額分別為人民幣 2.447 億元和人民幣 8730 萬元，同比增長 14.1% 和 42.6%。該券商維持 “買入” 評級，給予百濟神州（ONC.US）美國股票目標價為 403.8 美元，香港股票目標價為 243.83 港元。+1.100 (+0.610%) 空頭頭寸為 5562 萬美元；比例為 15.363%。（ha/w）（香港股票報價延遲至少 15 分鐘。空頭數據截至 2026-04-27 16:25。）（實時流式美國股票報價；除所有場外交易報價外，均至少延遲 15 分鐘。）</p>
<p>本文由 AI 自動翻譯，中文版本應視為權威版本。AASTOCKS.com Limited 不保證其準確性或完整性，並對因使用此翻譯而產生的任何損害或損失不承擔任何責任。</p>

百濟神州

鵬華上證科創板生物醫藥ETF

博時恆生港股通創新藥精選ETF

華寶恆生港股通創新藥精選ETF

易方達恆生港股通創新藥ETF

<p>BofAS 對百濟神州維持買入評級，目標價為 243.83 港元。該公司在中國的藥品總銷售額在 2 月份為 6.024 億元人民幣，同比增長 17.7%。自研和引進產品的銷售額分別為 3.322 億元人民幣和 2.698 億元人民幣，同比增長 20.3% 和 14.5%。值得注意的是，替雷利珠單抗和扎努布單抗的銷售額分別達到 2.447 億元人民幣和 8730 萬元人民幣，同比增長 14.1% 和 42.6%</p>

<p>BofAS issued a report stating that BEIGENE (06160.HK) +1.100 (+0.610%)  Short selling $55.62M; Ratio 15.363%  recorded total sample drug sales in China of RMB602.4 million in February, up 17.7% YoY. Sales of self-developed and in-licensed products reached RMB332.2 million and RMB269.8 million, rising 20.3% YoY and 14.5% YoY, respectively. Among them, sales of tislelizumab and zanubrutinib in February were RMB244.7 million and RMB87.3 million, representing YoY growth of 14.1% and 42.6%, respectively. The broker maintained its Buy rating, with a US stock TP of USD403.8 for BEIGENE (ONC.US) and a Hong Kong stock TP of HKD243.83 for BEIGENE (06160.HK) +1.100 (+0.610%)  Short selling $55.62M; Ratio 15.363%  . (ha/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-27 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)</p>
<div class="lb-trans"><p>美銀證券發佈報告稱，百濟神州（06160.HK）+1.100 (+0.610%) 空頭頭寸為 5562 萬美元；比例為 15.363%。2 月份在中國的樣本藥品總銷售額為人民幣 6.024 億元，同比增長 17.7%。自研和引進產品的銷售額分別達到人民幣 3.322 億元和人民幣 2.698 億元，分別同比增長 20.3% 和 14.5%。其中，2 月份的替雷利珠單抗和扎努布單抗的銷售額分別為人民幣 2.447 億元和人民幣 8730 萬元，同比增長 14.1% 和 42.6%。該券商維持 “買入” 評級，給予百濟神州（ONC.US）美國股票目標價為 403.8 美元，香港股票目標價為 243.83 港元。+1.100 (+0.610%) 空頭頭寸為 5562 萬美元；比例為 15.363%。（ha/w）（香港股票報價延遲至少 15 分鐘。空頭數據截至 2026-04-27 16:25。）（實時流式美國股票報價；除所有場外交易報價外，均至少延遲 15 分鐘。）</p>
</div><p>This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.</p>
<div class="lb-trans"><p>本文由 AI 自動翻譯，中文版本應視為權威版本。AASTOCKS.com Limited 不保證其準確性或完整性，並對因使用此翻譯而產生的任何損害或損失不承擔任何責任。</p>
</div>

BofAS Maintains Buy on BEIGENE  with TP at HKD243.83

AASTOCKS News

美國銀行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

美銀證券維持對百濟神州的買入評級，目標價定為 243.83 港元